In our previous study, we reported the high yield production of recombinant IFNα2–Tα1 comprising IFNα2 and Tα1 for use as a substitute of IFNα2 and Tα1, which are used in combination for hepatitis and cancer therapy. The gene discussed is IFNA2; the disease is cancer.